FI64801C - Foerfarande foer framstaellning av n-heterocyklyl-4-piperidinaminer med verkan av antihistamin - Google Patents

Foerfarande foer framstaellning av n-heterocyklyl-4-piperidinaminer med verkan av antihistamin Download PDF

Info

Publication number
FI64801C
FI64801C FI791084A FI791084A FI64801C FI 64801 C FI64801 C FI 64801C FI 791084 A FI791084 A FI 791084A FI 791084 A FI791084 A FI 791084A FI 64801 C FI64801 C FI 64801C
Authority
FI
Finland
Prior art keywords
group
formula
parts
benzimidazol
compounds
Prior art date
Application number
FI791084A
Other languages
English (en)
Finnish (fi)
Other versions
FI64801B (fi
FI791084A (fi
Inventor
Frans Janssens
Raymond Stokbroekx
Joseph Torremans
Marcel Luyckx
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26670178&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI64801(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US06/002,276 external-priority patent/US4219559A/en
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of FI791084A publication Critical patent/FI791084A/fi
Application granted granted Critical
Publication of FI64801B publication Critical patent/FI64801B/fi
Publication of FI64801C publication Critical patent/FI64801C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
FI791084A 1978-04-03 1979-04-02 Foerfarande foer framstaellning av n-heterocyklyl-4-piperidinaminer med verkan av antihistamin FI64801C (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US89253478A 1978-04-03 1978-04-03
US89253478 1978-04-03
US06/002,276 US4219559A (en) 1979-01-10 1979-01-10 N-Heterocyclyl-4-piperidinamines
US227679 1979-01-10

Publications (3)

Publication Number Publication Date
FI791084A FI791084A (fi) 1979-10-04
FI64801B FI64801B (fi) 1983-09-30
FI64801C true FI64801C (fi) 1984-01-10

Family

ID=26670178

Family Applications (1)

Application Number Title Priority Date Filing Date
FI791084A FI64801C (fi) 1978-04-03 1979-04-02 Foerfarande foer framstaellning av n-heterocyklyl-4-piperidinaminer med verkan av antihistamin

Country Status (29)

Country Link
EP (1) EP0005318B1 (da)
JP (2) JPS54151982A (da)
AT (1) AT373887B (da)
AU (1) AU523352B2 (da)
BG (1) BG38164A3 (da)
CA (1) CA1140119A (da)
CS (1) CS256358B2 (da)
CY (1) CY1250A (da)
DE (1) DE2961740D1 (da)
DK (1) DK169325B1 (da)
EG (1) EG13913A (da)
ES (1) ES479206A1 (da)
FI (1) FI64801C (da)
GR (1) GR64907B (da)
HK (1) HK3184A (da)
HU (1) HU182965B (da)
IE (1) IE47818B1 (da)
IL (1) IL56992A (da)
MY (1) MY8500046A (da)
NO (2) NO154058C (da)
NZ (1) NZ189978A (da)
PH (1) PH15877A (da)
PL (1) PL123380B1 (da)
PT (1) PT69429A (da)
RO (1) RO79320A (da)
SG (1) SG29883G (da)
SU (1) SU1056902A3 (da)
YU (2) YU42484B (da)
ZA (1) ZA791557B (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA19091A1 (fr) * 1980-03-10 1981-10-01 Janssen Pharmaceutica Nv Nouveaux derives de i-(4-aryl-cyclohexyl)piperidine .
US4556660A (en) * 1982-07-12 1985-12-03 Janssen Pharmaceutica N.V. N-(Bicyclic heterocyclyl)-4-piperidinamines
IN156065B (da) * 1982-07-12 1985-05-04 Janssen Pharmaceutica Nv
US4634704A (en) * 1983-10-06 1987-01-06 Janssen Pharmaceutica, N.V. Anti-allergic five membered heterocyclic ring containing N-(bicyclic heterocycyl)-4-piperidinamines
DE3484096D1 (de) * 1983-11-30 1991-03-14 Janssen Pharmaceutica Nv Bizyklisches heterozyklyl aufveisende n-(bizyklisches heterozyklyl-4-piperidinamine.
PL144514B1 (en) * 1984-01-09 1988-06-30 Janssen Pharmaceutica Nv Method of obtaining novel derivatives of n-/4-piperidinolo/-2-imidazoloamine
KR930005004B1 (ko) * 1985-04-15 1993-06-11 쟈안센 파아마슈우티카 엔. 부이. 치환된 n-[(4-피페리디닐)알킬]이환 축합 옥사졸아민 및 티아졸아민의 제조방법
GB8515934D0 (en) * 1985-06-24 1985-07-24 Janssen Pharmaceutica Nv (4-piperidinomethyl and-hetero)purines
ATE79620T1 (de) * 1986-02-03 1992-09-15 Janssen Pharmaceutica Nv N-heterozyklische-4-piperidinamine enthaltende anti-histaminische zusammensetzungen.
NZ223654A (en) * 1987-03-09 1990-03-27 Janssen Pharmaceutica Nv 1-alkyl-substituted-benzimidazole-4-piperidinamines and pharmaceutical compositions
FR2618435B1 (fr) * 1987-07-23 1989-10-27 Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
US5210091A (en) * 1991-06-24 1993-05-11 Neurosearch A/S Imidazole compounds and their use
US5624948A (en) * 1993-05-20 1997-04-29 Kissei Pharmaceutical Co., Ltd. 1-(2-benzimidazolyl)-1,5-diazacyclooctane compounds
US5547966A (en) * 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
AU3408999A (en) * 1998-03-06 1999-09-20 Janssen Pharmaceutica N.V. Glycine transport inhibitors
CZ20014574A3 (cs) * 1999-06-28 2002-05-15 Janssen Pharmaceutica N. V. Inhibitory replikace respiračně syncyciálního viru
CA2376676C (en) 1999-06-28 2009-01-20 Janssen Pharmaceutica N.V. Respiratory syncytial virus replication inhibitors
DE60033859T2 (de) * 1999-06-28 2007-11-08 Janssen Pharmaceutica N.V. Hemmer des Respiratorischen Syncytial Virus
DK1787984T3 (da) 2000-03-06 2017-01-30 Acadia Pharm Inc Azacykliske forbindelser til anvendelse til behandling af serotoninrelaterede sygdomme
PL368563A1 (en) 2001-02-02 2005-04-04 Teva Pharmaceutical Industries Ltd. Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1h-benzimidazoles
CN101050215A (zh) 2001-12-28 2007-10-10 阿卡蒂亚药品公司 作为单胺受体调节剂的螺氮杂环化合物
EP2316469A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
KR20050008846A (ko) 2002-06-24 2005-01-21 아카디아 파마슈티칼스 인코포레이티드 세로토닌 수용체 제제로서의 ｎ-치환된 피페리딘 유도체
KR101095939B1 (ko) 2003-01-16 2011-12-19 아카디아 파마슈티칼스 인코포레이티드 신경퇴행성 질환에 대한 치료제로서 선택적 세로토닌2ａ／2ｃ 리셉터 역작용제
ATE501135T1 (de) * 2003-12-18 2011-03-15 Tibotec Pharm Ltd Piperidinamino-benzimidazol-derivate al respiratorisches syncytialvirus replikation inhibitoren
TWI382981B (zh) 2003-12-18 2013-01-21 Tibotec Pharm Ltd 作為呼吸道融合病毒複製抑制劑之５-或６-經取代的苯并咪唑衍生物
DK1697343T3 (da) 2003-12-18 2009-10-05 Tibotec Pharm Ltd Aminobenzimidazoler og benzimidazoler som inhibitorer af replikation af respiratorisk syncytialvirus
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
US7732615B2 (en) 2004-09-27 2010-06-08 Acadia Pharmaceuticals Inc. N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
AU2008228833B9 (en) 2007-03-19 2013-10-24 Acadia Pharmaceuticals Inc. Combinations of 5-HT2A inverse agonists and antagonists with antipsychotics
EP3325444B1 (en) 2015-07-20 2021-07-07 Acadia Pharmaceuticals Inc. Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
US11464768B2 (en) 2016-12-20 2022-10-11 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis
EP3615028A1 (en) 2017-04-28 2020-03-04 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
WO2019046167A1 (en) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2857391A (en) * 1955-04-15 1958-10-21 Merck & Co Inc Aminomethylbenzimidazoles
US2971005A (en) * 1958-10-17 1961-02-07 Merck & Co Inc Nu-substituted derivatives of 2-benzylaminobenzimidazoles
BE788065A (fr) * 1971-08-26 1973-02-26 Degussa Nouvelles aza-benzimidazoles et procede pour leur preparation

Also Published As

Publication number Publication date
YU78479A (en) 1983-10-31
AU523352B2 (en) 1982-07-22
NO154090C (no) 1986-07-16
SU1056902A3 (ru) 1983-11-23
PL214648A1 (da) 1980-03-24
YU50283A (en) 1983-12-31
AU4529679A (en) 1979-10-18
ES479206A1 (es) 1979-12-16
NZ189978A (en) 1984-05-31
JPS641477B2 (da) 1989-01-11
MY8500046A (en) 1985-12-31
DK129879A (da) 1979-10-04
YU42484B (en) 1988-10-31
JPH0240666B2 (da) 1990-09-12
IE47818B1 (en) 1984-06-27
SG29883G (en) 1984-04-19
PH15877A (en) 1983-04-13
FI64801B (fi) 1983-09-30
NO154058C (no) 1986-07-09
CY1250A (en) 1984-08-31
IE790676L (en) 1979-10-03
ATA242579A (de) 1983-07-15
EP0005318B1 (en) 1982-01-06
ZA791557B (en) 1980-11-26
NO791097L (no) 1979-10-04
CA1140119A (en) 1983-01-25
DE2961740D1 (en) 1982-02-25
EP0005318A1 (en) 1979-11-14
IL56992A (en) 1983-03-31
HU182965B (en) 1984-03-28
PT69429A (pt) 1979-05-01
RO79320A (ro) 1982-08-17
NO842563L (no) 1979-10-04
GR64907B (en) 1980-06-07
JPS54151982A (en) 1979-11-29
EG13913A (en) 1982-09-30
IL56992A0 (en) 1979-07-25
CS222779A2 (en) 1987-03-12
CS256358B2 (en) 1988-04-15
DK169325B1 (da) 1994-10-10
YU43158B (en) 1989-04-30
NO154058B (no) 1986-04-01
NO154090B (no) 1986-04-07
AT373887B (de) 1984-02-27
JPH01117880A (ja) 1989-05-10
HK3184A (en) 1984-01-20
PL123380B1 (en) 1982-10-30
BG38164A3 (en) 1985-10-15
FI791084A (fi) 1979-10-04

Similar Documents

Publication Publication Date Title
FI64801C (fi) Foerfarande foer framstaellning av n-heterocyklyl-4-piperidinaminer med verkan av antihistamin
US4219559A (en) N-Heterocyclyl-4-piperidinamines
FI81797C (fi) Foerfarande foer framstaellning av en fem-ledad heterocyklisk ring innehaollande terapeutiskt aktiva n-(bicyklisk heterocyklyl)-4-piperidinaminer.
DE3882556T2 (de) 1-Alkyl-substituierte Benzimidazolderivate.
FI78480B (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara n-(bicyklis heterocyklyl)-4-piperidinaminderivat.
FI82046C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara bensoxazol-, bensotiazol- och tiazolopyridinaminer.
US6391878B2 (en) Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists
EP1848696A1 (en) Imidazole and benzimidazole derivates useful as histamine h3 antagonists
Janssens et al. New antihistaminic N-heterocyclic 4-piperidinamines. 2. Synthesis and antihistaminic activity of 1-[(4-fluorophenyl) methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-amines
FI62667B (fi) Foerfarande foer framstaellning av antiemetiska 1-(benzazolylalkyl)piperidinderivat
CA2600507C (en) 1,3-dihydro-benzimidazol-2-ylidene amines as inhibitors of respiratory syncytial virus replication
FI90233B (fi) Menetelmä uusien, terapeuttisesti käyttökelpoisten furanyylimetyylisubstituoitujen bentsimidatsoli- ja imidatsopyridiinijohdannaisten valmistamiseksi
CZ183699A3 (cs) 2-Imidazolinylaminobenzoxazolové sloučeniny užitečné jako alfa-2 adrenoceptorové agonisty
JPH01228986A (ja) ［（５（６）（１ｈ―アゾール―１―イルメチル）ベンズイミダゾール］カーバメート
RU2188822C2 (ru) Производное бензимидазола и средство, обладающее антагонистической активностью против вещества р и антигистаминовой активностью
DK171841B1 (da) N-hetero-cyclyl-4-piperidinaminer
JPH0413666A (ja) １―（アルコキシフェニル）―３―（４，５，６，７―テトラヒドロベンズイミダゾリル）ウレア
KR810001715B1 (ko) 5-[4-(디아릴메틸)-1-피페라지닐알킬〕벤즈이미다졸 유도체의 제조방법
Jha Department of Chemistry, Acadia University, Wolfville, B4P 2R6, Nova Scotia, Canada E-mail: amitabh. jha@ acadiau. ca
FI84070B (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara imidazopyridinylaminopiperidinderivat och mellanprodukter anvaendbara i foerfarandet.

Legal Events

Date Code Title Description
MA Patent expired
MA Patent expired

Owner name: JANSSEN PHARMACEUTICA N.V.